Problem or solution: The strange story of glucagon
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Globally, 13% of the world's adult population is obese, and more than 400 million people suffer from diabetes. These conditions are both associated with significant morbidity, mortality and financial cost. Therefore, finding new pharmacological treatments is an imperative. Relative hyperglucagonaemia is seen in all types of diabetes, and has been implicated in its pathogenesis. Consequently, clinical trials are underway using drugs which block glucagon activity to treat type 2 diabetes. Conversely, exogenous glucagon can increase energy expenditure. Therefore, researchers are designing peptides that combine activation of the glucagon receptor with further incretin properties, which will treat obesity while mitigating the hyperglycaemic effects of glucagon. This review will discuss these conflicting physiological properties of glucagon, and the attempts to harness these effects pharmacologically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012 · cited 1×
“ment, as typically drugs which increase energy expenditure also cause an increase in food intake [75,76], which means there is likely to be no overall loss of weight; and conversely, but equally problematically for an obesity treatment, reducing food intake is usually accompanied by a decrease in energy expenditure, w…”
BackgroundStudies of pancreatic alpha cell function in normal and diabetic subjects
Unger, R. H., Aguilar-Parada, E., Müller, W. A., & Eisentraut, A. M. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106297 · Cited by 837
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“This may be because of a reduction in metabolic rate which accompanies the weight loss [84].”
BackgroundSubcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
Self-citationWynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363 · cited 3×
“Moreover, this weight loss is not accompanied by any deterioration in glucose tolerance [78,79].”
BackgroundMethodSelf-citationGlucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327 · cited 1×
“Compared to wild-type mice, Gcgr-/- mice have constitutively lower blood glucose levels, improved glucose homeostasis and a lean phenotype [41]; they are also resistant to the hyperglycaemic and hyperinsulinaemic effects of highfat diet, and following beta-cell destruction with streptozotocin, have normal glucose leve…”
BackgroundThe effect of experimental insulin deficiency on glucagon secretion
Müller, W. A., Faloona, G. R., & Unger, R. H. (1971) · Journal of Clinical Investigation · doi:10.1172/jci106691 · Cited by 240
Conarello, S. L., Jiang, G., Mu, J., Li, Z., Woods, J., Zycband, E., Ronan, J., Liu, F., Roy, R. S., Zhu, L., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0481-3 · Cited by 224
Banarer, S., McGregor, V. P., & Cryer, P. E. (2002) · Diabetes · doi:10.2337/diabetes.51.4.958 · Cited by 194
Finan, B., Clemmensen, C., Zhu, Z., Stemmer, K., Gauthier, K., Müller, L., De Angelis, M., Moreth, K., Neff, F., Perez-Tilve, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.014 · Cited by 191
Guzman, C. B., Zhang, X. M., Liu, R., Regev, A., Shankar, S., Garhyan, P., Pillai, S. G., Kazda, C., Chalasani, N., & Hardy, T. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12958 · Cited by 172
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
Salem, V., Izzi‐Engbeaya, C., Coello, C., Thomas, D. B., Chambers, E. S., Comninos, A. N., Buckley, A., Win, Z., Al‐Nahhas, A., Rabiner, E. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12585 · Cited by 167
Self-citationCoinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake
Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., et al. (2014) · Diabetes · doi:10.2337/db14-0242 · Cited by 159
Self-citationTaborsky, G. J., & Mundinger, T. O. (2012) · Endocrinology · doi:10.1210/en.2011-2040 · Cited by 140 · cited 1×
“mulates glucagon release [7,9], and intra-islet glucose levels affect glucagon production as well [9].”
BackgroundGoldgof, M., Xiao, C., Chanturiya, T., Jou, W., Gavrilova, O., & Reitman, M. L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.568204 · Cited by 138 · cited 1×
“ment, as typically drugs which increase energy expenditure also cause an increase in food intake [75,76], which means there is likely to be no overall loss of weight; and conversely, but equally problematically for an obesity treatment, reducing food intake is usually accompanied by a decrease in energy expenditure, w…”
BackgroundIntra-Islet Somatostatin Regulates Glucagon Release via Type 2 Somatostatin Receptors in Rats
Cejvan, K., Coy, D. H., & Efendic, S. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1176 · Cited by 110
Kelly, R. P., Garhyan, P., Raddad, E., Fu, H., Lim, C. N., Prince, M. J., Pinaire, J. A., Loh, M. T., & Deeg, M. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12446 · Cited by 110 · cited 1×
“All can exaggerate a fall in blood sugar, with the potential for serious hypoglycaemia, though the number of symptomatic hypoglycaemic episodes actually seen in clinical trials is low [57,58,66,67].”
BackgroundJall, S., Sachs, S., Clemmensen, C., Finan, B., Neff, F., DiMarchi, R. D., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.02.002 · Cited by 107
Okamoto, H., Kim, J., Aglione, J., Lee, J., Cavino, K., Na, E., Rafique, A., Kim, J. H., Harp, J., Valenzuela, D. M., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1011 · Cited by 100 · cited 1×
“Pre-clinical studies have also shown that glucagon receptor antibodies cause compensatory alpha cell hyperplasia [51,52].”
BackgroundMetabolic effects of glucagon in the Wistar rat
SALTER, J. M. (1960) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/8.5.535 · Cited by 85 · cited 1×
“1960, Salter showed through a pair-feeding paradigm that glucagon causes an increase in energy expenditure in rodents [70], an increase that was confirmed by indirect calorimetry [71].”
BackgroundGlucagon receptor antagonism induces increased cholesterol absorption
Guan, H.-P., Yang, X., Lu, K., Wang, S.-P., Castro-Perez, J. M., Previs, S., Wright, M., Shah, V., Herath, K., Xie, D., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m060897 · Cited by 76 · cited 1×
“The small molecule glucagon receptor antagonists also increase LDL cholesterol, a highly undesirable side effect given the association of increased cholesterol, type 2 diabetes and cardiovascular disease [60,61,67,68]; and one, LY2409012, causes an increase in hepatic fat fraction [66].”
BackgroundBlockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist
Damond, N., Thorel, F., Moyers, J. S., Charron, M. J., Vuguin, P. M., Powers, A. C., & Herrera, P. L. (2016) · eLife · doi:10.7554/elife.13828 · Cited by 74
Cited by
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Recent advances in understanding the role of glucagon-like peptide 1
Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66
Glucagon, from past to present: a century of intensive research and controversies
Scheen, A. J., & Lefèbvre, P. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00349-7 · Cited by 44
Retatrutide—A Game Changer in Obesity Pharmacotherapy
Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., & Tsioufis, K. (2025) · Biomolecules · doi:10.3390/biom15060796 · Cited by 29
“It consists of 29 amino acids [29] and its gene is located on chromosome 2 [30].”
Metadata
- Authors
- Scott, R. V., & Bloom, S. R.
- Venue
- Peptides
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 100
- Pages
- 36-41
- ISSN
- 0196-9781 (ISSN-L)
- OpenAlex
- W2791055036
- Cited by
- 54
- References
- 26
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.